The Marked Chart Wire · Health
VK2735
Viking Therapeutics reports VK2735 trial results showing BMI improvements
Viking Therapeutics announced that 74 percent of participants taking subcutaneous VK2735 improved their BMI category after 13 weeks, compared with 15 percent on placebo. The company also noted improvements in cardiometabolic markers.
